Biocompatibility Innovation

Biocompatibility Innovation

Biocompatibility Innovation Srl (BCI) shareholders have been working as scientific researchers for more than 15 years at University level, in Italian and American Institutions, in the field of cardiovascular Tissue Engineering and Regenerative Medicine. BCI is a biotech company acting as services provider for private and public Institutions. Actually, BCI is focused on two new fields of application: - development of novel methods to help manufacturing companies in producing highly biocompatible xenogeneic tissues for clinical applications. As matter of fact, BCI patented two methods for the quantification of xenogenic antigen in soft tissues and for their inactivation. Moreover, has a strong background on the biochemical and structural changes affecting the extracellular matrix (ECM) as the result of different detergent-based decellularizzation processes; - development of novel industrial processes to increase the biocompatibility of foods, limiting allergies insurgence and host immune-mediated reaction and chronic inflammation.

Ufficio stampa

PR Account
user
Filippo Naso